女性不妊診断・治療市場：製品、治療、診断、不妊原因、エンドユーザー別-2025-2030年世界予測

女性不妊診断・治療市場は、2023年に18億1,000万米ドルと評価され、2024年には19億6,000万米ドルに達すると予測され、CAGR 8.11％で成長し、2030年には31億4,000万米ドルに達すると予測されています。

女性の不妊診断・治療市場には、女性の不妊症の診断と治療に使用される様々な方法と技術が含まれ、生理的な原因と生活習慣に関連する原因の両方に対処します。このようなソリューションの必要性は、妊娠の遅れ、ホルモンバランスの乱れ、平均出産年齢の上昇などの要因による不妊率の増加によってもたらされ、効率的な診断・治療システムの必要性が強調されています。応用範囲には、体外受精（IVF）、卵巣刺激プロトコル、外科的介入、投薬などの生殖補助医療（ART）が主に含まれます。最終用途には、不妊治療クリニック、病院、手術センターなどが含まれ、これらは的を絞ったソリューションを提供するため、研究投資や政府支援によって重要な市場セグメントを形成しています。

市場の洞察によると、主な成長要因としては、生殖技術の進歩、不妊治療に対する認識と受容の高まり、ヘルスケア支出の増加などが挙げられます。さらに、ART治療への保険適用を提供する政府の取り組みや公衆衛生キャンペーンは、市場拡大の潜在的機会となっています。医療インフラが整備されつつあるインドと中国は、特に現地の医療提供者との提携や協力を通じて大きな可能性を秘めた新興市場です。しかし、治療費の高騰、後発開発途上地域の認識不足、ARTに関する倫理的懸念などの制約が課題となっています。さらに、農村部では先進医療技術の普及が限られているため、市場への浸透が制限されています。

技術革新と研究の最良の分野としては、費用対効果が高く利用しやすい不妊治療ソリューションの開発、ART技術の強化、患者モニタリングと個別化治療計画のためのデジタル技術の統合などが挙げられます。さらに、不妊に影響を与える遺伝的要因やライフスタイル要因の調査により、新たな治療の道が開ける可能性があります。市場の性質はダイナミックであり、継続的な技術的・規制的変化が利害関係者の適応戦略を必要としています。新たな機会の獲得を目指す企業にとって、バイオテクノロジー企業との協力関係を育み、認知度向上キャンペーンに注力し、顧客中心の調査に取り組むことが、課題を克服して成長を促すために最も重要です。

市場力学：急速に進化する女性不妊診断・治療市場における主要市場インサイトの解明

女性不妊診断・治療市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 女性の生殖・不妊問題の有病率の上昇
  • リプロダクティブ・ヘルスケア・ソリューションへのアクセスを促進する政府の取り組み
  • 不妊治療クリニックの世界の拡大と生殖問題に対する意識の拡大
• 市場抑制要因
  • 熟練した人材の不足と不妊問題の特定と治療の複雑さ
• 市場機会
  • 女性不妊診断・治療ソリューションの有効性と精度を向上させるための継続的な技術革新
  • 生殖問題を管理するための新たな技術革新やソリューションに対する規制当局の好意的な支援
• 市場の課題
  • 女性不妊診断・治療ソリューションの精度と副作用に関する治療上の懸念

ポーターのファイブフォース：女性不妊診断・治療市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：女性不妊診断・治療市場における外部からの影響の把握

外部マクロ環境要因は、女性不妊診断・治療市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析女性不妊診断・治療市場における競合情勢の把握

女性不妊診断・治療市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス女性不妊診断・治療市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、女性不妊診断・治療市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨女性不妊診断・治療市場における成功への道筋を描く

女性不妊診断・治療市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大の可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 女性における生殖および不妊の問題の増加
    • 生殖ヘルスケアソリューションへのアクセスを促進する政府の取り組み
    • 世界中で不妊治療クリニックが拡大し、生殖問題に対する意識が高まっている
  • 抑制要因
    • 熟練した人材の不足と不妊の問題の特定と治療の複雑さ
  • 機会
    • 女性不妊症の診断と治療ソリューションの有効性と精度を向上させるための継続的なイノベーション
    • 生殖問題を管理するための新たなイノベーションとソリューションに対する好ましい規制支援
  • 課題
    • 女性不妊症の診断と治療ソリューションの正確性と副作用に関する懸念
• 市場セグメンテーション分析
  • 製品：体外での胚の成長と生存をサポートする培地ソリューションの導入拡大
  • エンドユーザー：不妊治療クリニックの専門的生殖ケアの第一選択
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 女性不妊診断・治療市場：製品別

• アクセサリー
• 装置
• メディア

第7章 女性不妊診断・治療市場治療別

• 生殖補助医療
• 薬物治療
• 手術

第8章 女性不妊診断・治療市場診断別

• 子宮鏡検査
• 画像検査
• 排卵検査

第9章 女性不妊診断・治療市場不妊の原因別

• 子宮内膜症
• 排卵障害
• 卵管閉塞

第10章 女性不妊診断・治療市場：エンドユーザー別

• 不妊治療クリニック
• 病院
• 調査機関

第11章 南北アメリカの女性不妊診断・治療市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋地域の女性不妊診断・治療市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカの女性不妊診断・治療市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • ルピン、米国市場に新たなジェネリック不妊治療を導入
  • インド人女性のための革新的な在宅不妊検査、Arva Health社
  • Trajan Scientificとドイツのスタートアップ Fertillyがマイクロサンプリングベースの不妊検査キットを欧州で導入
• 戦略分析と提言

企業一覧

• Bayer AG
• Cook Group Incorporated
• CooperSurgical Inc.
• Ferring B.V.
• FUJIFILM Irvine Scientific, Inc. by FUJIFILM Holdings Corporation
• Genea Pty Limited
• GlaxoSmithKline PLC
• Halotech DNA S.L.
• Intas Pharmaceuticals Ltd.
• Lupin Limited
• Merck & Co., Inc.
• Novartis AG
• Sanofi SA
• SCSA Diagnostics, Inc.
• Theramex by Kanga Health Ltd
• Vitrolife Sweden AB

LIST OF FIGURES

• FIGURE 1. FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET RESEARCH PROCESS
• FIGURE 2. FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CAUSE OF INFERTILITY, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CAUSE OF INFERTILITY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. AMERICAS FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. AMERICAS FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. UNITED STATES FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 19. UNITED STATES FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. ASIA-PACIFIC FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 23. EUROPE, MIDDLE EAST & AFRICA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 25. FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET DYNAMICS
• TABLE 7. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ACCESSORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY EQUIPMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY MEDIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY MEDICATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY HYSTEROSCOPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY IMAGING TESTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY OVULATION TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CAUSE OF INFERTILITY, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ENDOMETRIOSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY OVULATORY DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TUBAL OCCLUSION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY FERTILITY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CAUSE OF INFERTILITY, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 33. ARGENTINA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 34. ARGENTINA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 35. ARGENTINA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 36. ARGENTINA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CAUSE OF INFERTILITY, 2018-2030 (USD MILLION)
• TABLE 37. ARGENTINA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 38. BRAZIL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 39. BRAZIL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 40. BRAZIL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 41. BRAZIL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CAUSE OF INFERTILITY, 2018-2030 (USD MILLION)
• TABLE 42. BRAZIL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 43. CANADA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 44. CANADA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 45. CANADA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 46. CANADA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CAUSE OF INFERTILITY, 2018-2030 (USD MILLION)
• TABLE 47. CANADA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 48. MEXICO FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 49. MEXICO FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 50. MEXICO FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 51. MEXICO FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CAUSE OF INFERTILITY, 2018-2030 (USD MILLION)
• TABLE 52. MEXICO FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 53. UNITED STATES FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 54. UNITED STATES FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 55. UNITED STATES FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 56. UNITED STATES FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CAUSE OF INFERTILITY, 2018-2030 (USD MILLION)
• TABLE 57. UNITED STATES FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 58. UNITED STATES FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 59. ASIA-PACIFIC FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 60. ASIA-PACIFIC FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 61. ASIA-PACIFIC FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 62. ASIA-PACIFIC FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CAUSE OF INFERTILITY, 2018-2030 (USD MILLION)
• TABLE 63. ASIA-PACIFIC FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 64. ASIA-PACIFIC FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 65. AUSTRALIA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 66. AUSTRALIA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 67. AUSTRALIA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 68. AUSTRALIA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CAUSE OF INFERTILITY, 2018-2030 (USD MILLION)
• TABLE 69. AUSTRALIA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 70. CHINA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 71. CHINA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 72. CHINA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 73. CHINA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CAUSE OF INFERTILITY, 2018-2030 (USD MILLION)
• TABLE 74. CHINA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 75. INDIA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 76. INDIA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 77. INDIA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 78. INDIA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CAUSE OF INFERTILITY, 2018-2030 (USD MILLION)
• TABLE 79. INDIA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 80. INDONESIA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 81. INDONESIA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 82. INDONESIA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 83. INDONESIA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CAUSE OF INFERTILITY, 2018-2030 (USD MILLION)
• TABLE 84. INDONESIA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 85. JAPAN FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 86. JAPAN FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 87. JAPAN FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 88. JAPAN FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CAUSE OF INFERTILITY, 2018-2030 (USD MILLION)
• TABLE 89. JAPAN FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 90. MALAYSIA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 91. MALAYSIA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 92. MALAYSIA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 93. MALAYSIA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CAUSE OF INFERTILITY, 2018-2030 (USD MILLION)
• TABLE 94. MALAYSIA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 95. PHILIPPINES FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 96. PHILIPPINES FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 97. PHILIPPINES FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 98. PHILIPPINES FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CAUSE OF INFERTILITY, 2018-2030 (USD MILLION)
• TABLE 99. PHILIPPINES FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 100. SINGAPORE FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 101. SINGAPORE FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 102. SINGAPORE FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 103. SINGAPORE FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CAUSE OF INFERTILITY, 2018-2030 (USD MILLION)
• TABLE 104. SINGAPORE FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 105. SOUTH KOREA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 106. SOUTH KOREA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 107. SOUTH KOREA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 108. SOUTH KOREA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CAUSE OF INFERTILITY, 2018-2030 (USD MILLION)
• TABLE 109. SOUTH KOREA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 110. TAIWAN FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 111. TAIWAN FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 112. TAIWAN FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 113. TAIWAN FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CAUSE OF INFERTILITY, 2018-2030 (USD MILLION)
• TABLE 114. TAIWAN FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 115. THAILAND FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 116. THAILAND FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 117. THAILAND FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 118. THAILAND FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CAUSE OF INFERTILITY, 2018-2030 (USD MILLION)
• TABLE 119. THAILAND FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 120. VIETNAM FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 121. VIETNAM FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 122. VIETNAM FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 123. VIETNAM FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CAUSE OF INFERTILITY, 2018-2030 (USD MILLION)
• TABLE 124. VIETNAM FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 125. EUROPE, MIDDLE EAST & AFRICA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 126. EUROPE, MIDDLE EAST & AFRICA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 127. EUROPE, MIDDLE EAST & AFRICA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 128. EUROPE, MIDDLE EAST & AFRICA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CAUSE OF INFERTILITY, 2018-2030 (USD MILLION)
• TABLE 129. EUROPE, MIDDLE EAST & AFRICA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 130. EUROPE, MIDDLE EAST & AFRICA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 131. DENMARK FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 132. DENMARK FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 133. DENMARK FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 134. DENMARK FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CAUSE OF INFERTILITY, 2018-2030 (USD MILLION)
• TABLE 135. DENMARK FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 136. EGYPT FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 137. EGYPT FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 138. EGYPT FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 139. EGYPT FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CAUSE OF INFERTILITY, 2018-2030 (USD MILLION)
• TABLE 140. EGYPT FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 141. FINLAND FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 142. FINLAND FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 143. FINLAND FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 144. FINLAND FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CAUSE OF INFERTILITY, 2018-2030 (USD MILLION)
• TABLE 145. FINLAND FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 146. FRANCE FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 147. FRANCE FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 148. FRANCE FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 149. FRANCE FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CAUSE OF INFERTILITY, 2018-2030 (USD MILLION)
• TABLE 150. FRANCE FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 151. GERMANY FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 152. GERMANY FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 153. GERMANY FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 154. GERMANY FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CAUSE OF INFERTILITY, 2018-2030 (USD MILLION)
• TABLE 155. GERMANY FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 156. ISRAEL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 157. ISRAEL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 158. ISRAEL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 159. ISRAEL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CAUSE OF INFERTILITY, 2018-2030 (USD MILLION)
• TABLE 160. ISRAEL FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 161. ITALY FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 162. ITALY FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 163. ITALY FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 164. ITALY FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CAUSE OF INFERTILITY, 2018-2030 (USD MILLION)
• TABLE 165. ITALY FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 166. NETHERLANDS FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 167. NETHERLANDS FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 168. NETHERLANDS FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 169. NETHERLANDS FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CAUSE OF INFERTILITY, 2018-2030 (USD MILLION)
• TABLE 170. NETHERLANDS FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 171. NIGERIA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 172. NIGERIA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 173. NIGERIA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 174. NIGERIA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CAUSE OF INFERTILITY, 2018-2030 (USD MILLION)
• TABLE 175. NIGERIA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 176. NORWAY FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 177. NORWAY FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 178. NORWAY FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 179. NORWAY FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CAUSE OF INFERTILITY, 2018-2030 (USD MILLION)
• TABLE 180. NORWAY FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 181. POLAND FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 182. POLAND FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 183. POLAND FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 184. POLAND FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CAUSE OF INFERTILITY, 2018-2030 (USD MILLION)
• TABLE 185. POLAND FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 186. QATAR FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 187. QATAR FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 188. QATAR FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 189. QATAR FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CAUSE OF INFERTILITY, 2018-2030 (USD MILLION)
• TABLE 190. QATAR FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 191. RUSSIA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 192. RUSSIA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 193. RUSSIA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 194. RUSSIA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CAUSE OF INFERTILITY, 2018-2030 (USD MILLION)
• TABLE 195. RUSSIA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 196. SAUDI ARABIA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 197. SAUDI ARABIA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 198. SAUDI ARABIA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 199. SAUDI ARABIA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CAUSE OF INFERTILITY, 2018-2030 (USD MILLION)
• TABLE 200. SAUDI ARABIA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 201. SOUTH AFRICA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 202. SOUTH AFRICA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 203. SOUTH AFRICA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 204. SOUTH AFRICA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CAUSE OF INFERTILITY, 2018-2030 (USD MILLION)
• TABLE 205. SOUTH AFRICA FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 206. SPAIN FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 207. SPAIN FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 208. SPAIN FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 209. SPAIN FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CAUSE OF INFERTILITY, 2018-2030 (USD MILLION)
• TABLE 210. SPAIN FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 211. SWEDEN FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 212. SWEDEN FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 213. SWEDEN FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 214. SWEDEN FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CAUSE OF INFERTILITY, 2018-2030 (USD MILLION)
• TABLE 215. SWEDEN FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 216. SWITZERLAND FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 217. SWITZERLAND FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 218. SWITZERLAND FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 219. SWITZERLAND FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CAUSE OF INFERTILITY, 2018-2030 (USD MILLION)
• TABLE 220. SWITZERLAND FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 221. TURKEY FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 222. TURKEY FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 223. TURKEY FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 224. TURKEY FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CAUSE OF INFERTILITY, 2018-2030 (USD MILLION)
• TABLE 225. TURKEY FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 226. UNITED ARAB EMIRATES FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 227. UNITED ARAB EMIRATES FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 228. UNITED ARAB EMIRATES FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 229. UNITED ARAB EMIRATES FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CAUSE OF INFERTILITY, 2018-2030 (USD MILLION)
• TABLE 230. UNITED ARAB EMIRATES FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 231. UNITED KINGDOM FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 232. UNITED KINGDOM FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 233. UNITED KINGDOM FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 234. UNITED KINGDOM FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CAUSE OF INFERTILITY, 2018-2030 (USD MILLION)
• TABLE 235. UNITED KINGDOM FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 236. FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 237. FEMALE INFERTILITY DIAGNOSIS & TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

The Female Infertility Diagnosis & Treatment Market was valued at USD 1.81 billion in 2023, expected to reach USD 1.96 billion in 2024, and is projected to grow at a CAGR of 8.11%, to USD 3.14 billion by 2030.

The female infertility diagnosis and treatment market encompasses various methods and technologies used to diagnose and treat infertility in women, addressing both physiological and lifestyle-related causes. The necessity for these solutions is driven by increasing infertility rates due to factors such as delayed pregnancies, hormonal imbalances, and rising average ages at childbirth, emphasizing the need for efficient diagnosis and treatment systems. Application scope primarily involves assisted reproductive technologies (ART) like in-vitro fertilization (IVF), ovarian stimulation protocols, surgical interventions, and medication. End-use includes fertility clinics, hospitals, and surgical centers, which provide targeted solutions, thereby forming a crucial market segment driven by research investments and governmental support.

Market insights reveal that key growth factors include advancements in reproductive technologies, increased awareness and acceptance of infertility treatments, and rising healthcare expenditures. Further, government initiatives providing insurance coverage for ART procedures and public health campaigns are potential opportunities to expand market reach. India and China, with their growing healthcare infrastructures, represent emerging markets with significant potential, particularly through collaborations and partnerships with local healthcare providers. However, limitations such as high costs of treatment, lack of awareness in less developed regions, and ethical concerns regarding ART pose challenges. Moreover, the limited reach of advanced medical technologies in rural areas restricts market penetration.

The best areas for innovation and research include developing cost-effective and accessible fertility treatment solutions, enhancements in ART techniques, and digital technology integration for patient monitoring and personalized treatment plans. Additionally, research into genetic and lifestyle factors affecting fertility could unveil new treatment avenues. The market nature is dynamic, with continuous technological and regulatory changes necessitating adaptive strategies for stakeholders. For businesses aiming to seize emerging opportunities, fostering collaborations with biotechnology firms, focusing on awareness campaigns, and engaging in customer-centric research will be paramount to navigate challenges and stimulate growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Female Infertility Diagnosis & Treatment Market

The Female Infertility Diagnosis & Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising prevalence of reproductive and fertility issues among women
  • Government initiatives to promote access to reproductive healthcare solutions
  • Expansion of fertility clinics across the world and expanding awareness about reproductive issues
• Market Restraints
  • Lack of skilled personnel and complexity of identifying and treating fertility issues
• Market Opportunities
  • Ongoing innovations to improve the effectiveness and accuracy of female infertility diagnosis and treatment solutions
  • Favorable regulatory support for new innovations and solutions for managing reproductive issues
• Market Challenges
  • Concerns related to the accuracy and side effects of female infertility diagnosis and treatment solutions

Porter's Five Forces: A Strategic Tool for Navigating the Female Infertility Diagnosis & Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Female Infertility Diagnosis & Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Female Infertility Diagnosis & Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Female Infertility Diagnosis & Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Female Infertility Diagnosis & Treatment Market

A detailed market share analysis in the Female Infertility Diagnosis & Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Female Infertility Diagnosis & Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Female Infertility Diagnosis & Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Female Infertility Diagnosis & Treatment Market

A strategic analysis of the Female Infertility Diagnosis & Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Female Infertility Diagnosis & Treatment Market, highlighting leading vendors and their innovative profiles. These include Bayer AG, Cook Group Incorporated, CooperSurgical Inc., Ferring B.V., FUJIFILM Irvine Scientific, Inc. by FUJIFILM Holdings Corporation, Genea Pty Limited, GlaxoSmithKline PLC, Halotech DNA S.L., Intas Pharmaceuticals Ltd., Lupin Limited, Merck & Co., Inc., Novartis AG, Sanofi SA, SCSA Diagnostics, Inc., Theramex by Kanga Health Ltd, and Vitrolife Sweden AB.

Market Segmentation & Coverage

This research report categorizes the Female Infertility Diagnosis & Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product, market is studied across Accessories, Equipment, and Media.
• Based on Treatment, market is studied across Assisted Reproductive Technology, Medication, and Surgery.
• Based on Diagnosis, market is studied across Hysteroscopy, Imaging Tests, and Ovulation Testing.
• Based on Cause of Infertility, market is studied across Endometriosis, Ovulatory Disorders, and Tubal Occlusion.
• Based on End User, market is studied across Fertility Clinics, Hospitals, and Research Institutes.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of reproductive and fertility issues among women
    • 5.1.1.2. Government initiatives to promote access to reproductive healthcare solutions
    • 5.1.1.3. Expansion of fertility clinics across the world and expanding awareness about reproductive issues
  • 5.1.2. Restraints
    • 5.1.2.1. Lack of skilled personnel and complexity of identifying and treating fertility issues
  • 5.1.3. Opportunities
    • 5.1.3.1. Ongoing innovations to improve the effectiveness and accuracy of female infertility diagnosis and treatment solutions
    • 5.1.3.2. Favorable regulatory support for new innovations and solutions for managing reproductive issues
  • 5.1.4. Challenges
    • 5.1.4.1. Concerns related to the accuracy and side effects of female infertility diagnosis and treatment solutions
• 5.2. Market Segmentation Analysis
  • 5.2.1. Product: Increasing incorporation of media solutions as it support the growth and viability of embryos outside the body
  • 5.2.2. End User: Fertility clinics' first-line choice for specialized reproductive care
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Female Infertility Diagnosis & Treatment Market, by Product

• 6.1. Introduction
• 6.2. Accessories
• 6.3. Equipment
• 6.4. Media

7. Female Infertility Diagnosis & Treatment Market, by Treatment

• 7.1. Introduction
• 7.2. Assisted Reproductive Technology
• 7.3. Medication
• 7.4. Surgery

8. Female Infertility Diagnosis & Treatment Market, by Diagnosis

• 8.1. Introduction
• 8.2. Hysteroscopy
• 8.3. Imaging Tests
• 8.4. Ovulation Testing

9. Female Infertility Diagnosis & Treatment Market, by Cause of Infertility

• 9.1. Introduction
• 9.2. Endometriosis
• 9.3. Ovulatory Disorders
• 9.4. Tubal Occlusion

10. Female Infertility Diagnosis & Treatment Market, by End User

• 10.1. Introduction
• 10.2. Fertility Clinics
• 10.3. Hospitals
• 10.4. Research Institutes

11. Americas Female Infertility Diagnosis & Treatment Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Female Infertility Diagnosis & Treatment Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Female Infertility Diagnosis & Treatment Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
  • 14.3.1. Lupin Introduces New Generic Infertility Treatment in the U.S. Market
  • 14.3.2. Arva Health's Innovative At-Home Fertility Test for Indian Women
  • 14.3.3. Trajan Scientific and German Startup Fertilly Introduce Microsampling-based Fertility Test Kits in Europe
• 14.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Bayer AG
• 2. Cook Group Incorporated
• 3. CooperSurgical Inc.
• 4. Ferring B.V.
• 5. FUJIFILM Irvine Scientific, Inc. by FUJIFILM Holdings Corporation
• 6. Genea Pty Limited
• 7. GlaxoSmithKline PLC
• 8. Halotech DNA S.L.
• 9. Intas Pharmaceuticals Ltd.
• 10. Lupin Limited
• 11. Merck & Co., Inc.
• 12. Novartis AG
• 13. Sanofi SA
• 14. SCSA Diagnostics, Inc.
• 15. Theramex by Kanga Health Ltd
• 16. Vitrolife Sweden AB